Globus Medical, Inc. $GMED Shares Sold by Banque Pictet & Cie SA

Key Points

• Banque Pictet & Cie SA reduced its position in Globus Medical by 34.5%, selling 14,806 shares and now holding 28,121 shares valued at $2.455 million.
• Globus Medical beat quarterly expectations with EPS of $1.28 vs. $1.06 est. and revenue of $826.4M vs. $803.3M (up 25.7% YoY), and analysts have issued multiple upgrades leaving a consensus "Moderate Buy" price target of $104.36.
• Insiders sold a total of 35,594 shares this quarter worth about $3.33 million — notably EVP Kelly Huller sold 20,000 shares at $94.50 and Director Leslie Norwalk sold 2,000 at $101.10 — with insiders now owning 18.51% of the stock.

Banque Pictet & Cie SA decreased its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 34.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,121 shares of the medical device company's stock after selling 14,806 shares during the quarter. Banque Pictet & Cie SA's holdings in Globus Medical were worth $2,455,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GMED. Advisory Services Network LLC acquired a new stake in shares of Globus Medical during the 3rd quarter valued at approximately $26,000. EverSource Wealth Advisors LLC increased its stake in Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company's stock valued at $27,000 after purchasing an additional 197 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Globus Medical during the second quarter worth $28,000. First Horizon Corp bought a new position in shares of Globus Medical in the 3rd quarter worth about $31,000. Finally, Parallel Advisors LLC boosted its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company's stock valued at $32,000 after buying an additional 173 shares during the period. 95.16% of the stock is currently owned by institutional investors.

More Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks raised its Q1 2028 EPS forecast to $1.20 (from $1.19) and reiterated a "Strong‑Buy" rating — a direct, recent upgrade to near‑term earnings expectations that can boost investor confidence. MarketBeat GMED
• Positive Sentiment: Multiple small upward revisions across quarters (Q1–Q3 2026, Q1–Q3 2027) and fiscal years (FY2026, FY2027, FY2028) — including FY2026 to $4.42, FY2027 to $4.67 and FY2028 to $5.19 — suggest Zacks is modeling modestly stronger revenue/profit trends over the next several years. This broad-based upgrade pattern is a constructive signal for growth expectations. MarketBeat GMED
• Neutral Sentiment: Valuation and technical backdrop: GMED trades with a market cap ~ $11.9B and a P/E ~22x; the stock sits near its 50‑day moving average (~$88.9) above the 200‑day (~$80.8). These factors moderate how quickly upgrades translate into price moves — investors will watch upcoming results and guidance for confirmation. MarketBeat GMED

Analyst Upgrades and Downgrades

GMED has been the topic of several research reports. Citigroup reissued a "market perform" rating on shares of Globus Medical in a report on Thursday, January 8th. Wall Street Zen raised Globus Medical from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 3rd. Royal Bank Of Canada raised their price target on Globus Medical from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, December 17th. TD Cowen upgraded Globus Medical to a "strong-buy" rating in a research report on Tuesday, January 27th. Finally, Canaccord Genuity Group upped their price objective on Globus Medical from $105.00 to $112.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $104.36.

Insider Transactions at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of the company's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares of the company's stock, valued at $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kelly Huller sold 20,000 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 35,594 shares of company stock valued at $3,332,253. 18.51% of the stock is currently owned by corporate insiders.

Globus Medical Trading Down 0.0%

Shares of NYSE:GMED opened at $87.72 on Friday. The firm's 50 day moving average is $88.88 and its two-hundred day moving average is $80.81. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The firm has a market capitalization of $11.86 billion, a P/E ratio of 22.26, a PEG ratio of 2.05 and a beta of 1.09.

Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.22. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.The business had revenue of $826.42 million during the quarter, compared to the consensus estimate of $803.29 million. During the same period in the previous year, the firm posted $0.84 earnings per share. The business's revenue was up 25.7% on a year-over-year basis. Analysts predict that Globus Medical, Inc. will post 3.44 EPS for the current year.

Globus Medical Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.